Status:
RECRUITING
A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia
Lead Sponsor:
Shandong University
Conditions:
Pneumonia
Eligibility:
All Genders
65-100 years
Phase:
NA
Brief Summary
Pneumonia is characterized by high incidence and mortality rates in elderly patients (≥65 years old). Piperacillin-tazobactam, as a broad-spectrum antibiotic, has its therapeutic efficacy and safety p...
Eligibility Criteria
Inclusion
- Age must be greater than 65 years Clinical diagnosis of Pneumonia Receiving intravenous piperacillin-tazobactam treatment
Exclusion
- History of allergy to β-lactam antibiotics Continuous renal replacement therapy, severe organ dysfunction Malignant tumor disease
Key Trial Info
Start Date :
July 24 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT06972537
Start Date
July 24 2024
End Date
September 30 2026
Last Update
May 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Second hospital of Shandong university
Jinan, Shandong, China, 250000